BB Biotech Q1 2025: Portfolio Adjustments Amid Volatile Market

BB Biotech reported a challenging Q1 2025, marked by market volatility and geopolitical uncertainty. The company recorded a net loss of CHF 241 million, with the share price closing at a 14.1% discount to NAV. Despite a share price decline of 8.8% in CHF and 10.3% in EUR, BB Biotech continued to refine its portfolio strategy.

The investment team introduced a new position in Akero Therapeutics, reflecting confidence in its pipeline, while exiting positions in companies like Intra-Cellular Therapies and Fate Therapeutics. The portfolio now comprises 23 positions, focusing more on companies above USD 1 billion in market cap.

Regulatory milestones included FDA approvals for Vertex’s JOURNAVX™ and an expanded indication for Alnylam’s Amvuttra. Despite macroeconomic headwinds, BB Biotech remains committed to long-term investments in innovative biotech solutions.